Provided by Tiger Trade Technology Pte. Ltd.

Galera Therapeutics, Inc.

0.0240
-0.0012-4.76%
Volume:53.28K
Turnover:1.34K
Market Cap:1.81M
PE:-0.10
High:0.0283
Open:0.0240
Low:0.0240
Close:0.0252
52wk High:0.0598
52wk Low:0.0151
Shares:75.46M
Float Shares:56.72M
Volume Ratio:0.95
T/O Rate:0.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2462
EPS(LYR):-0.3470
ROE:-1063.11%
ROA:-55.36%
PB:-0.01
PE(LYR):-0.07

Loading ...

Company Profile

Company Name:
Galera Therapeutics, Inc.
Exchange:
OTCQB
Establishment Date:
2012
Employees:
3
Office Location:
101 Lindenwood Drive,Suite 225,Malvern,Pennsylvania,United States
Zip Code:
19355
Fax:
- -
Introduction:
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also developing GC4711, a dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.